Stay updated with breaking news from Nilotinib Capsules. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Eugia Pharma has signed a voluntary sub-licensing agreement with Medicines Patent Pool to make and sell Nilotinib capsules, originally developed by Novartis, for chronic myeloid leukemia in 44 low and middle-income countries
The product will be produced at the Eugia Pharma Specialities Ltd. Unit-I, Medchal, Malkajgiri District, Telangana, India.
Shares of Aurobindo Pharma went up by 3% after the company announced that its subsidiary Eugia Pharma has signed a voluntary license with Medicines Patent Pool to create and market a generic version of Nilotinib Capsules. Aurobindo Pharmas wholly-owned subsidiary Eugia Pharma Specialities has entered a voluntary sublicensing agreement with Medicines Patent Pool to manufacture and market the drug in 44 low and middle-income countries for the treatment of chronic myeloid leukemia.